Satellos details June investor conference presentations
Rhea-AI Filing Summary
Satellos Bioscience Inc. announced that its management team will present at two investor conferences in June. The company will speak at the Jefferies Global Healthcare Conference on June 4, 2026 at 11:05 a.m. in New York, and at the Oppenheimer CNS & Neuro-Muscular Summit on June 10, 2026 at 10:15 a.m. in Miami. Presentations will be available via live webcast on Satellos’ investor relations site, with replays afterward, and management will hold one-on-one meetings with investors. Satellos is a clinical-stage drug developer advancing SAT-3247, an orally administered small molecule targeting AAK1, in two Phase II trials for Duchenne muscular dystrophy, one in pediatric patients (BASECAMP) and one in adults (TRAILHEAD).
Positive
- None.
Negative
- None.
Key Figures
Jefferies conference presentation time: 11:05 a.m.
Oppenheimer summit panel time: 10:15 a.m.
Conference month: June 2026
+2 more
5 metrics
Jefferies conference presentation time
11:05 a.m.
Jefferies Global Healthcare Conference on June 4, 2026 in New York
Oppenheimer summit panel time
10:15 a.m.
Oppenheimer CNS & Neuro-Muscular Summit on June 10, 2026 in Miami
Conference month
June 2026
Investor conferences where Satellos will participate
Lead program phase
Phase II
Clinical trials for SAT-3247 in Duchenne muscular dystrophy
Number of Phase II trials
2 trials
BASECAMP in pediatrics and TRAILHEAD in adults for SAT-3247
Key Terms
Phase II clinical trials, dystrophin-independent, orally administered small molecule therapy, adjunctive therapy, +1 more
5 terms
Phase II clinical trials financial
"in two Phase II clinical trials: BASECAMP in pediatrics and TRAILHEAD in adults"
Phase II clinical trials are studies that evaluate whether an experimental drug or therapy actually works and is reasonably safe in a larger group of patients after initial safety checks. Investors care because results provide the first meaningful evidence of effectiveness and side effects—like a prototype tested with real users—informing whether a program is likely to advance, shaping a drug’s future value and the company’s funding and partnership prospects.
dystrophin-independent medical
"in a dystrophin-independent manner. This mechanistic feature offers SAT-3247 the potential"
orally administered small molecule therapy medical
"a first-of-its-kind, orally administered small molecule therapy designed to reset the body’s natural muscle repair"
adjunctive therapy medical
"as either a stand-alone treatment to potentially enhance muscle and function, or as adjunctive therapy alongside other approaches"
Adjunctive therapy is a treatment given in addition to a primary therapy to boost its effectiveness, reduce side effects, or treat related symptoms — like adding a side dish to make a main meal work better. For investors, evidence that an adjunctive therapy improves outcomes, safety, or convenience can expand a product’s use, support stronger regulatory labeling and reimbursement, and increase commercial potential by reaching more patients or strengthening a therapy’s market position.
AAK1 medical
"SAT-3247 targets AAK1, a protein that is a key regulator of the body’s natural muscle repair"
AAK1 is a human gene that makes a protein acting like a traffic controller inside cells, helping move and sort molecules into and out of the cell. Investors care because drugs that block or modify AAK1 can change how cells handle infections or neurological signals, so evidence that a therapy affects AAK1 can influence the value of biotech pipelines, clinical trial prospects, and future regulatory or commercial outcomes.
FAQ
What did Satellos Bioscience Inc. (MSLE) announce in this 6-K?
Satellos announced participation in two June investor conferences and highlighted progress of its lead drug SAT-3247. Management will present, host one-on-one investor meetings, and provide webcast access to presentations through the company’s investor relations website with replays available afterward.
When and where will Satellos (MSLE) present to investors in June 2026?
Satellos will present at the Jefferies Global Healthcare Conference on June 4, 2026 at 11:05 a.m. in New York, and at the Oppenheimer CNS & Neuro-Muscular Summit on June 10, 2026 at 10:15 a.m. in Miami, with webcast access available.
What is Satellos’ lead drug candidate SAT-3247?
SAT-3247 is an orally administered small molecule therapy designed to reset muscle repair and regeneration. It targets the AAK1 protein and is being developed as a potential disease-modifying treatment for degenerative muscle diseases, initially focusing on Duchenne muscular dystrophy patients.
Which clinical trials are evaluating SAT-3247 for Duchenne muscular dystrophy?
SAT-3247 is in two Phase II trials for Duchenne muscular dystrophy. The BASECAMP study focuses on pediatric patients, while the TRAILHEAD study focuses on adults, reflecting Satellos’ strategy to evaluate the drug across different age groups with this degenerative muscle disease.
How is SAT-3247 designed to work in degenerative muscle diseases?
SAT-3247 inhibits AAK1, a protein Satellos identified as key to muscle repair biology and disrupted in DMD. By blocking AAK1, it aims to restore biochemical signaling guiding muscle regeneration in a dystrophin-independent way, potentially allowing use alone or together with other treatments.
Will Satellos’ June 2026 conference presentations be available online?
Yes. Satellos plans to provide a live webcast of its conference presentation through the Events and Presentations section of its investor relations website. A replay will be available after the event, allowing investors and other interested parties to review the discussion later.
AI-generated analysis. How Rhea-AI works. Not financial advice.
